XBiotech Statistics
Share Statistics
XBiotech has 30.49M
shares outstanding. The number of shares has increased by 0.1%
in one year.
| Shares Outstanding | 30.49M |
| Shares Change (YoY) | 0.1% |
| Shares Change (QoQ) | 0.01% |
| Owned by Institutions (%) | 15.48% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 383 |
| FTD / Avg. Volume | 0.68% |
Short Selling Information
The latest short interest is 898.58K, so 2.95% of the outstanding
shares have been sold short.
| Short Interest | 898.58K |
| Short % of Shares Out | 2.95% |
| Short % of Float | 5.03% |
| Short Ratio (days to cover) | 14.63 |
Valuation Ratios
The PE ratio is -3.12 and the forward
PE ratio is null.
XBiotech's PEG ratio is
-0.06.
| PE Ratio | -3.12 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | 0.66 |
| P/FCF Ratio | -3.73 |
| PEG Ratio | -0.06 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for XBiotech.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.56,
with a Debt / Equity ratio of 0.06.
| Current Ratio | 11.56 |
| Quick Ratio | 11.56 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | -0.28 |
| Debt / FCF | -0.32 |
| Interest Coverage | -52.63 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-418,815.22 |
| Employee Count | 92 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -32K |
| Effective Tax Rate | 0.08% |
Stock Price Statistics
The stock price has increased by -64.06% in the
last 52 weeks. The beta is 0.97, so XBiotech's
price volatility has been higher than the market average.
| Beta | 0.97 |
| 52-Week Price Change | -64.06% |
| 50-Day Moving Average | 3.1 |
| 200-Day Moving Average | 5.14 |
| Relative Strength Index (RSI) | 52.52 |
| Average Volume (20 Days) | 56,417 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -42.47M |
| Net Income | -38.53M |
| EBITDA | -36.01M |
| EBIT | -39.37M |
| Earnings Per Share (EPS) | -1.26 |
Full Income StatementBalance Sheet
The company has 172.68M in cash and 10.25M in
debt, giving a net cash position of 162.43M.
| Cash & Cash Equivalents | 172.68M |
| Total Debt | 10.25M |
| Net Cash | 162.43M |
| Retained Earnings | -90.84M |
| Total Assets | 181.86M |
| Working Capital | 152.28M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -30.96M
and capital expenditures -1.3M, giving a free cash flow of -32.27M.
| Operating Cash Flow | -30.96M |
| Capital Expenditures | -1.3M |
| Free Cash Flow | -32.27M |
| FCF Per Share | -1.06 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
